Drug intelligence / Profile preview

ZMC003

Development stage: Preclinical
Lead developer: Zymedi
Modality: Small Molecules

Overview

ZMC003 is a novel small molecule drug developed by Zymedi that acts as a specific inhibitor of the pro-inflammatory activities of secreted lysyl-tRNA synthetase (KARS1). By targeting KARS1, ZMC003 aims to reduce inflammation and fibrosis. Preclinical studies have demonstrated significant efficacy in reducing lobular inflammation, fibrosis, and steatosis in multiple models of metabolic dysfunction-associated steatotic liver disease (MASH). The compound is currently in preclinical development for this indication[1][2].

Targets

aaRS (Aminoacyl-tRNA synthetase family)

Beyond the preview

Go deeper on ZMC003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZMC003.

Explore the full profile